Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081 PHASE2 COMPLETED Results posted

The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	COMPLETED
Enrolment	385
Start date	Thu Jul 05 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Nov 26 2008 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Infections, Meningococcal

Interventions

• Meningococcal vaccine GSK134612

Countries

United States